MAPT and Alzheimer disease: Numbers of clinical trials results also demonstrated that HLJDD has the effect of treating AD, including reducing the levels of β-amyloid, phosphorylated tau protein and inflammatory factors (Chen and Guan, 2016; Jeon et al., 2019), reducing the aggressiveness of dementia patients (Okamoto et al., 2013) and improving deviation and rejection behaviors (Qi et al., 2019; Urabe et al., 2020).